Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Michael Garrett House

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1676-8124; OpenAlex author ID A5063009124. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 4 papers

Papers 27

  1. Commentary on "Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: updated systematic review, individual-patient-data meta-analysis an… Co-author DOI 10.1016/j.surg.2026.110124↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18539-4↗
  4. ASO Visual Abstract: Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancrea… Co-author DOI 10.1245/s10434-025-18724-5↗
  5. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  6. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  7. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  8. Invited commentary for "Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer". Co-author DOI 10.1016/j.surg.2024.03.010↗
  9. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  10. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  11. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? Co-author DOI 10.1002/jso.27289↗
  12. Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarci… Co-author DOI 10.1016/j.surg.2022.06.046↗
  13. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Co-author DOI 10.3390/cancers13081975↗
  14. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Last author DOI 10.1007/s11605-020-04723-2↗
  15. Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? Co-author DOI 10.1016/j.jss.2019.12.036↗
  16. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Co-author DOI 10.1002/jcsm.12461↗
  17. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? Co-author DOI 10.1002/jso.25376↗
  18. Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.09.007↗
  19. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. Co-author DOI 10.1007/s00464-017-5633-7↗
  20. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancrea… Co-author DOI 10.1097/coc.0000000000000409↗
  21. Prospective Evaluation of Associations between Cancer-Related Pain and Perineural Invasion in Patients with Resectable Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11605-017-3513-z↗
  22. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.02.019↗
  23. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. First author DOI 10.1007/s11605-015-3005-y↗
  24. MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. Co-author DOI 10.1007/s11605-016-3208-x↗
  25. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. Co-author DOI 10.1016/j.amjsurg.2014.10.017↗
  26. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2301-y↗
  27. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Co-author DOI 10.1016/j.surg.2011.07.048↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nicholas Joseph Zyromski · 13 shared papers, 2011–2023 · strength 1.26
  2. Eugene P. Ceppa · 11 shared papers, 2015–2023 · strength 1.14
  3. Christian Max Schmidt · 9 shared papers, 2015–2023 · strength 0.85
  4. Alexandra M. Roch · 6 shared papers, 2015–2023 · strength 0.66
  5. Alexa J. Hughes · 2 shared papers, 2026 · strength 0.60
  6. Kristen N. Kaiser · 2 shared papers, 2026 · strength 0.60
  7. Ryan J. Ellis · 2 shared papers, 2026 · strength 0.60
  8. Trang K. Nguyen · 3 shared papers, 2020–2023 · strength 0.47
  9. Henry Anthony Pitt · 4 shared papers, 2011–2024 · strength 0.42
  10. Christopher M. Schmidt · 4 shared papers, 2011–2023 · strength 0.38
  11. Rachel C. Kim · 2 shared papers, 2023 · strength 0.37
  12. Safi Shahda · 4 shared papers, 2018–2021 · strength 0.37
  13. Matthew H. G. Katz · 2 shared papers, 2024 · strength 0.31
  14. Bodil Andersson · 2 shared papers, 2024 · strength 0.31
  15. Karin U. Johansen · 2 shared papers, 2024 · strength 0.31
  16. Tobias Keck · 2 shared papers, 2024 · strength 0.31
  17. Michael B. Ghadimi · 2 shared papers, 2024 · strength 0.31
  18. Bergþór Björnsson · 2 shared papers, 2024 · strength 0.31
  19. Simone Augustinus · 2 shared papers, 2024 · strength 0.31
  20. Izaak Quintus Molenaar · 2 shared papers, 2024 · strength 0.31
  21. Susan van Dieren · 2 shared papers, 2024 · strength 0.31
  22. Tara M. Mackay · 2 shared papers, 2024 · strength 0.31
  23. Bobby Tingstedt · 2 shared papers, 2024 · strength 0.31
  24. Waldemar H. Uhl · 2 shared papers, 2024 · strength 0.31
  25. Ulrich Friedrich Wellner · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.